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Abstract
Background: For stereotactic body radiation therapy (SBRT) of liver tumors, tumor motion induced by respiration
must be taken into account in planning and treatment. We evaluated whether liver tumor motion at the planning
simulation represents liver tumor motion during SBRT, and estimated inter- and intrafractional tumor motion
changes in patients undergoing liver SBRT.
Methods: Ten patients underwent four-dimensional cone-beam computed tomography (4D-CBCT) image-guided
liver SBRT with abdominal compression (AC) and fiducial markers. 4D-CBCT was performed to evaluate liver tumor
motion at the planning simulation, pre-, and post-SBRT. The translational distances at the center position of the
fiducial markers from all 10 phases on the 4D-CBCT images were measured as the extent of the liver tumor motion
in the left-right (LR), anterior-posterior (AP), and superior-inferior (SI) directions. Pearson correlation coefficients were
calculated to evaluate the correlation between liver tumor motion of the planning simulation and the mean liver
tumor motion of the pre-SBRT. Inter- and intrafractional liver tumor motion changes were measured based on the
4D-CBCT of planning simulation, pre-, and post-SBRT. Significant inter- and intrafractional changes in liver tumor
motion were defined as a change of >3 mm.
Results: The mean (± SD) liver tumor motion of the planning simulation 4D-CBCT was 1.7 ± 0.8 mm, 2.4 ± 2.2 mm,
and 5.3 ± 3.3 mm, in the LR, AP, and SI directions, respectively. Those of the pre-SBRT 4D-CBCT were 1.2 ± 0.7 mm,
2.3 ± 2.3 mm, and 4.5 ± 3.8 mm, in the LR, AP, and SI directions, respectively. There was a strong significant correlation
between liver tumor motion of the planning simulation and pre-SBRT in the LR (R = 0.7, P < 0.01), AP (R = 0.9, P < 0.01),
and SI (R = 0.9, P < 0.01) directions. Significant inter- and intrafractional liver tumor motion changes occurred in 10 and
2% of treatment fractions, respectively.
Conclusions: Liver tumor motion at the planning simulation represents liver tumor motion during SBRT. Inter- and
intrafractional liver tumor motion changes were small in patients with AC.
Keywords: Liver tumor, Four-dimensional cone-beam computed tomography, Image-guided radiotherapy,
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Background
Stereotactic body radiation therapy (SBRT) for liver
tumors has been introduced as alternatives to stand-
ard treatment modalities such as surgical resection
and radiofrequency ablation. SBRT delivers a highly
conformal, potent dose of radiation to the tumor in a
limited number of fractions while minimizing radi-
ation damage to organs at risk [1]. To prescribe an
accurate radiation dose to liver tumors, inter- and
intrafractional motion, induced by respiration, must
be taken into account during planning simulation and
treatment [2–5]. However, unlike lung tumors, liver
tumors are difficult to visualize due to the lack of soft
tissue contrast of image-guided radiotherapy modal-
ities, such as computed tomography (CT) and cone-
beam CT (CBCT) [6–8]. To address this issue, metal
fiducial markers, which are implanted in or near the
tumor, are used as tumor surrogates. Image guidance
with fiducial markers is reported as a more accurate
method than image guidance with the liver contour
or diaphragm position [2, 8–11].
The value of four-dimensional computed tomog-
raphy (4D-CT) is reported to define tumor contours
and the internal target volume (ITV) during respira-
tory movement in the RT treatment planning, assum-
ing that the tumor motion of 4D-CT at the planning
session represents the tumor motion throughout the
course of SBRT [3–5, 12–14]. However, 4D-CT is not
installed in all institutions. As a system for perform-
ing respiration-corrected CBCT, 4D-CBCT has been
used for image-guided SBRT for lung and liver
tumors [4, 15–18]. Park et al. [18] have performed
4D-CBCT using motion tracking of fiducial markers
during liver SBRT. They reported that 4D-CBCT
could significantly reduce motion-induced blurring of
fiducial markers and liver anatomy, and could be use-
ful for image-guided liver SBRT. Using 4D-CBCT,
Case et al. [4] reported that inter- and intrafractional
liver motion changes during liver SBRT in 29 patients
were <3 mm in 80% of the fractions. However, they
evaluated liver motion changes based on the dia-
phragm position, which may be inappropriate for the
evaluation of liver tumor motion.
In the previous report, intrafractional tumor motion
during free-breathing was investigated using a real-time
tumor tracking radiotherapy (RTRT) system and fiducial
markers for liver SBRT [2], but changes in the tumor
motion throughout the course of treatment were not
been fully evaluated. In this study, we evaluated whether
liver tumor motion at the planning simulation represents
liver tumor motion during SBRT, and estimated changes
of inter- and intrafractional tumor motion in patients
undergoing liver SBRT with abdominal compression
(AC) using 4D-CBCT and fiducial markers.
Methods
Patients
This retrospective study was approved by the institu-
tional review board of our hospital. Prior informed con-
sent for treatment and the use of 4D-CBCT and its
images for the study was obtained from all patients.
Between May 2014 and May 2016, 11 consecutive
patients underwent 4D-CBCT image-guided liver SBRT.
Of these, 10 patients were included in this study. One
patient was excluded because she refused AC because it
caused discomfort. Of the 10 patients, 5 patients had
hepatocellular carcinoma, 2 had cholangiocellular
carcinoma, and 3 had liver metastases. Liver tumors
were located in the segment 4 in 2, 5 in 2, 6 in 1, 7 in 2,
and 8 in 3 patients. The mean value of gross tumor
volume (GTV) was 10.9 mL (range, 0.4–45.9 mL). All
patients had 1–2 gold fiducial markers 2 mm in diam-
eter (iGold; Medikit, Tokyo, Japan) implanted in the liver
using the percutaneous transhepatic approach [19].
Planning simulation CT
All patients lay supine with their arms raised and were
immobilized with a system consisting of a vacuum bag,
thermoplastic body shell, and carbon base plate with a size
of 185 × 50 × 3 cm (length × width × height) (ESN-1800;
Engineering System, Nagano, Japan). Patients were
instructed to breathe shallowly for 1 minute to form a
body shell. AC was applied in all patients to achieve repro-
ducible tumor motion for planning and treatment; an in-
house beaded cushion was inserted inside the formed
body shell for AC. Multiphasic contrast-enhanced CT and
slow CT were performed during the free-breathing using
a LightSpeed RT CT scanner (GE Medical Systems,
Waukesha, WI). Contrast-enhanced scans with the helical
mode (rotation time: 1 s) were performed 30, 45, 70, and
180 s after the intravenous administration of a contrast
agent (Iopamiron 300, Bayer Schering Pharma, Osaka,
Japan) at a rate of 3 mL/s. A slow CT scan with the axial
mode (rotation time: 4 s) was performed immediately after
the completion of these contrast-enhanced scans. Both
sets of CT data were reconstructed in a field of view
(FOV) of 65 cm with a 2.5-mm slice thickness. All CT im-
ages were exported to the Pinnacle3 treatment planning
system (version 9.2; Phillips Radiation Oncology Systems,
Fitchburg, WI) and were registered by hardware
arrangement.
Estimation of the tumor motion on 4D-CBCT
On the same day of planning simulation CT, a 4D-CBCT
scan was performed to evaluate liver tumor motion for
the planning. The patient was positioned in the body
immobilization system and aligned at the machine’s iso-
center. The 4D-CBCT scans were acquired using the
Elekta Symmetry System (Elekta Oncology Systems,
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Crawley, UK) and the projection data were sorted into 10
respiratory-phase bins [15]. The acquisition parameters
were set in the small mode to 120 kV, 20 mA, 16 ms per
frame, and 2-mm slice thickness with an acquisition time
of 4 min. The small mode is designed to obtain projection
data from a 200° gantry rotation with an FOV of 27 cm×
26 cm. The 4D-CBCT data were reconstructed using a
2-mm voxel size. Tumor motion was measured using
Elekta XVI software (version 4.5; Elekta Oncology Systems,
Crawley, UK). The translational distances at the center po-
sitions of the fiducial markers (COM) from all 10 phases
on the 4D-CBCT images were measured as the extent of
the liver tumor motion in the left-right (LR), anterior-
posterior (AP), and superior-inferior (SI) directions (Fig. 1).
The COM was defined as the maximum intensity position
of the image pixels (minimum pixel size: 0.1 mm) using
the image probe function of XVI software. The coordinates
of COM were determined on the basis of each cross-
sectional image, and the maximum distances of the coord-
inate were calculated as the extent of the motion of the
liver tumor in LR, AP, and SI directions. In each patient,
fiducial markers were measured individually, with an
average of 1.8 markers, and a total of 18 markers [7].
Treatment planning
GTV was defined by reference to the contrast-enhanced
CT images and diagnostic magnetic resonance images.
Clinical target volume (CTV) was defined with 3D mar-
gins of 0–3 mm to the GTV. The ITV was defined by
applying margins to the CTV, which were based on the
calculated results of the tumor motion. The planning
target volume (PTV) was defined by adding margins
ranging from 1–3 mm, 1–3 mm, and 3–6 mm to the
ITV for the LR, AP, and SI directions, respectively. All
structures of these tumor and target volumes, and the
organs at risk (e.g., liver, gastrointestinal tract, spinal
cord, and kidneys) were delineated on the slow CT im-
ages. Each fiducial marker was also delineated, and a
covering volume with margins determined according to
calculated results of the tumor motion was generated on
the slow CT images, referred to as the “internal marker
target volume” (IMTV) [8]. All slow CT data and struc-
tures were exported into the Elekta XVI software as the
reference for image guidance.
Treatment planning was performed using 8–9 coplanar-
and noncoplanar fields with a 6-MV and/or 10-MV
photon beam on an Elekta Synergy with Agility multileaf
collimator (Elekta Oncology Systems). The beam angles
were chosen to minimize the treatment time while avoiding
transmission of the beam path through the organs at risk.
Treatment delivery
For liver SBRT target localization, 4D-CBCT was per-
formed in a similar manner as the planning simulation.
Fig. 1 Four-dimensional cone-beam computed tomography (4D-CBCT) images of the end-exhalation a, c and end-inhalation b, d. The “internal
marker target volume (IMTV)” structure (blue and orange) that reflected the motion of fiducial markers observed in 4D-CBCT were used for target
localization in liver SBRT
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Manual registration between images of 4D-CBCT and
slow CT was performed using the axial, coronal, and sagit-
tal views until moving images of the fiducial marker of all
10 phases in the 4D-CBCT images were symmetrically
positioned within the IMTV structure in the slow CT
images. (Fig. 1). After the confirmation of the appropriate
registration on the Elekta XVI software, the treatment
couch was repositioned with translational correction, and
liver SBRT was delivered. Immediately after treatment, a
4D-CBCT scan was performed to assess the intrafractional
setup error of the target position. The treatment time,
which was defined as the time from the beginning of the
pre-SBRT 4D-CBCT to that of the post-SBRT 4D-CBCT,
ranged from 11.1 to 25.7 min, with an average of
17.7 min.
Liver tumor motion analysis
The liver tumor motion analyses were performed based
on the coordinates of the COM from all 10 phases on
the 4D-CBCT images using the image probe function of
XVI software. For each patient, the mean and standard
deviation (SD) of liver tumor motion, and inter- and
intrafractional motion changes were calculated based
on the 4D-CBCT images of the planning simulation,
pre- and post-SBRT. The interfractional motion change
was calculated as the difference in the liver tumor pre-
SBRT relative to that of the planning simulation for
each fraction. The intrafractional motion change was
calculated as the difference between the liver tumor of
pre- and post-SBRT for each fraction. Significant inter-
and intrafractional changes in liver tumor motion were
defined as a change of >3 mm, which corresponded to
the threshold for the planning CT image resolution.
Pearson correlation coefficients were calculated to
evaluate correlations between liver tumor motion of
the planning simulation and the mean liver tumor
motion of the pre-SBRT. Statistical significance was
defined as P < 0.05. All statistical calculations were
Fig. 2 Correlation between liver tumor motion measured by planning simulation 4D-CBCT and mean liver tumor motion measured by pre-SBRT
4D-CBCT during five fraction treatments in the a left-right (LR), b anterior-posterior (AP), and c superior-inferior (SI) directions
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performed with SPSS software, version 24.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Correlation between liver tumor motion of the planning
simulation and pre-SBRT
For the 10 patients, the mean (± SD) liver tumor motions
of the planning simulation were 1.7 ± 0.8 mm (range, 0.6–
3.8 mm), 2.4 ± 2.2 mm (range, 0.3–9.4 mm), and 5.3 ±
3.3 mm (range, 1.5–14.8 mm) in the LR, AP, and SI direc-
tions, respectively. The mean (± SD) liver tumor motions
of pre-SBRT were 1.2 ± 0.7 mm (range, 0.3–3.3 mm),
2.3 ± 2.3 mm (range, 0.3–8.1 mm), and 4.5 ± 3.8 mm
(range, 0.7–14.3 mm) in the LR, AP, and SI directions, re-
spectively. Figure 2 shows the correlation between the
liver tumor motion of the planning simulation and the
mean liver tumor motion of the pre-SBRT. There was a
strong significant correlation in the LR (R = 0.7, P < 0.01),
AP (R = 0.9, P < 0.01), and SI (R = 0.9, P < 0.01) directions.
Inter- and intrafractional changes in liver tumor motion
The inter- and intrafractional liver tumor motion changes
are displayed graphically in Figs. 3 and 4, respectively. Mean
(± SD) absolute interfractional changes in the liver tumor
motion were 0.6 ± 0.5 mm (range, 0.1–2.4 mm), 0.8 ±
0.7 mm (range, 0.1–3.0 mm), and 1.3 ± 1.0 mm (range, 0.1–
3.6 mm) in the LR, AP, and SI directions, respectively. Inter-
fractional liver tumor motion changes of >3 mm occurred
in 10% of treatment fractions, in the SI direction alone.
Mean (± SD) absolute intrafractional changes in liver tumor
motion were 0.4 ± 0.3 mm (range, 0.1–1.9 mm), 0.6 ±
0.5 mm (range, 0.1–2.9 mm), and 0.7 ± 0.7 mm (range, 0.1–
3.8 mm) in the LR, AP, and SI directions, respectively. Intra-
fractional liver tumor motion changes of >3 mm occurred
in 2% of treatment fractions, in the SI direction alone.
Discussion
The 4D-CBCT accurately represented the tumor motion
range during reconstruction by sorting the projection
Fig. 3 Box plots of interfractional changes in liver tumor motion (pre-SBRT - planning simulation) by patient in the a left-right (LR), b anterior-posterior
(AP), and c superior-inferior (SI) directions. Lines represent ranges of liver tumor motion changes; boxes represent range from 25th to 75th percentile
in liver tumor motion changes
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data into multiple respiratory phases according to a
respiration signal [15]. From the results of liver tumor
motion, based on this state-of-the-art imaging modality,
there was a strong correlation between liver tumor
motion on the planning simulation and pre-SBRT. These
data suggested that liver tumor motion at the planning
simulation could represent liver tumor motion during
SBRT. Therefore, 4D-CBCT can be introduced for not
only treatment but also planning of liver SBRT as a
useful modality for the evaluation of tumor motion in
the institutions that do not have 4D-CT.
In the present study, the liver tumor motion pattern,
based on 4D-CBCT, was approximately 2–3 times larger
in the SI direction compared with the LR and AP direc-
tions. These motion patterns were similar to those in
previous studies that utilized RTRT system, 4D-CT, and
CBCT projection data [2, 10]. Kitamura et al. [2] investi-
gated the liver tumor motion during free breathing with-
out AC using RTRT and reported that the mean liver
tumor motions were 4 ± 4 mm, 5 ± 3 mm, and 9 ± 5 mm
in the LR, AP, and SI directions, respectively. Park et al.
[10] investigated liver tumor motion in patients
undergoing SBRT without AC using 4D-CT and CBCT,
and found that liver tumor motions were 3.0 ± 2.0 mm,
5.1 ± 3.1 mm, and 17.9 ± 4 mm based on 4D-CT, and
2.8 ± 1.6 mm, 5.3 ± 3.1 mm, and 16.5 ± 5.7 mm based on
CBCT, for the LR, AP, and SI directions, respectively.
On the other hand, in the present study, the liver tumor
motion ranges were smaller than those reported previ-
ously, most likely because we used AC [20]. Wunderink
et al. [20] measured the effect of AC on the respiratory
motion of liver tumors and concluded that AC reduced
liver tumor motion to <5 mm in the all three directions
in 10 of 12 patients. Therefore, AC use could effectively
reduce 3D liver tumor motion.
The present study found that liver tumor motion
changes were small in most patients who underwent
liver SBRT with AC, and inter- and intrafractional mo-
tion changes of >3 mm were rare in any direction. Case
et al. [4] investigated inter- and intrafractional liver
Fig. 4 Box plots of intrafractional changes in liver tumor motion (post-SBRT - pre-SBRT) by patient in the a left-right (LR), b anterior-posterior (AP),
and c superior-inferior (SI) directions. Lines represent ranges of liver tumor motion changes; boxes represent range from 25th to 75th percentile
in liver tumor motion changes
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motion changes in liver SBRT patients with or without
AC, based on 4D-CBCT using the diaphragm position.
They found that the mean absolute interfractional
changes were 1.0 mm, 1.6 mm, and 1.7 mm and the
mean intrafractional changes were 1.3 mm, 1.9 mm, and
1.6 mm for the LR, AP, and SI directions, respectively,
which were larger than those observed in the present
study. In addition to including the patients without AC,
these differences likely arose because methods for evalu-
ating liver tumor motion using the diaphragm position
could result in overestimation due to motion-induced
blurring of the diaphragm. For localization of the liver
tumor, Wunderink et al. [9] and Zhang et al. [11] reported
that the diaphragm position provided inaccurate SI set-up
measurements and had an absolute error of >3 mm, com-
pared with fiducial markers. Precise liver SBRT should be
realized by the combined use of 4D-CBCT and fiducial
markers at both the planning and treatment stages. More-
over, our results suggested that adding 3D margins of
3 mm or less to liver tumor motion at the planning simu-
lation might be adequate to cover the tumor motion at
the treatment if AC is available.
This present study had some limitations, including the
relatively small number of patients. We evaluated intra-
fractional changes based on 4D-CBCT scans before and
after liver SBRT because we could not measure intrafrac-
tional changes by monitoring the fiducial markers during
treatment. The development of a system for performing
in-treatment 4D-CBCT could address this issue [21].
Conclusions
In this paper, we evaluated the tumor motion of liver
SBRT with AC throughout the course of treatment
based on 4D-CBCT and fiducial markers. Liver tumor
motion at the planning simulation could represent liver
tumor motion in patients undergoing SBRT. Significant
inter- and intrafractional motion changes were rare in
most patients who underwent liver SBRT with AC. Pre-
cise liver SBRT should be realized by the combined use
of 4D-CBCT and fiducial markers at both the planning
and treatment stages.
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